Cover Image
市場調查報告書

異動症(dyskinesia):全球臨床實驗檢討

Dyskinesia Global Clinical Trials Review, H2, 2016

出版商 GlobalData 商品編碼 235312
出版日期 內容資訊 英文 213 Pages
訂單完成後即時交付
價格
Back to Top
異動症(dyskinesia):全球臨床實驗檢討 Dyskinesia Global Clinical Trials Review, H2, 2016
出版日期: 2016年10月31日 內容資訊: 英文 213 Pages
簡介

本報告提供異動症(dyskinesia)的治療藥相關臨床實驗調查分析,提供您最新趨勢,各階段及Phase狀況,有潛力的企業,開發中的治療藥資訊,臨床實驗簡介等相關的系統性資訊。

目錄

簡介

各地區的臨床實驗

  • 各國臨床實驗趨勢
    • 亞太地區的主要國家
    • 歐洲的主要國家
    • 北美的主要國家
    • 中東·非洲的主要國家
    • 中南美的主要國家

G7各國的臨床實驗:中樞神經系統臨床實驗上異動症(dyskinesia)的比例

G7各國的臨床實驗:Phase別

G7各國的臨床實驗:各階段

E7各國的臨床實驗:中樞神經系統臨床實驗上異動症(dyskinesia)的比例

E7各國的臨床實驗:Phase別

E7各國的臨床實驗:各階段

各方面的臨床實驗

各階段臨床實驗

評估項目別臨床實驗

未完成的臨床實驗

一定期間所採用的實驗對象

各類贊助商臨床實驗

有潛力的贊助商

  • 異動症(dyskinesia)治療藥臨床實驗的主要參與企業

有前途藥物

臨床實驗簡介

  • 主要企業臨床實驗概要
    • Ipsen S.A.
    • Neurocrine Biosciences, Inc.
    • Allergan, Inc.
    • Merz Pharma GmbH & Co. KgaA
    • Novartis AG
    • Auspex Pharmaceuticals, Inc.
    • UCB S.A.
    • Eisai
    • E. Merck KG
    • Adamas Pharmaceuticals, Inc.
  • 主要大學·研究機關·醫院臨床實驗概要
    • National Institute of Neurological Disorders and Stroke
    • University Health Network
    • University of Florida
    • Oregon Health & Science University
    • Leiden University Medical Center
    • Rush University Medical Center
    • Seoul National University Hospital
    • Taoyuan Mental Hospital
    • University of Iowa
    • Vanderbilt University

主要的臨床簡介

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC3847CTIDB

GlobalData's clinical trial report, "Dyskinesia Global Clinical Trials Review, H2, 2016" provides an overview of Dyskinesia clinical trials scenario. This report provides top line data relating to the clinical trials on Dyskinesia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Dyskinesia to Central Nervous System Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Dyskinesia to Central Nervous System Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Dyskinesia Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Clinical Trial Profile Snapshots 29

Appendix 210

  • Abbreviations 210
  • Definitions 210
  • Research Methodology 211
  • Secondary Research 211
  • About GlobalData 212
  • Contact Us 212
  • Disclaimer 212
  • Source 213

List of Tables

  • Dyskinesia Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Dyskinesia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Dyskinesia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
  • Dyskinesia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Dyskinesia Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Dyskinesia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
  • Dyskinesia Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
  • Proportion of Dyskinesia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
  • Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Dyskinesia to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
  • Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Dyskinesia Therapeutics, Global, Clinical Trials by Phase, 2016* 20
  • Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
  • Dyskinesia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Dyskinesia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Dyskinesia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Dyskinesia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
  • Dyskinesia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Dyskinesia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Dyskinesia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures

  • Dyskinesia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Dyskinesia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Dyskinesia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
  • Dyskinesia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Dyskinesia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Dyskinesia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
  • Dyskinesia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
  • Proportion of Dyskinesia to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
  • Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Dyskinesia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Dyskinesia to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
  • Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Dyskinesia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Dyskinesia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
  • Dyskinesia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
  • Dyskinesia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Dyskinesia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Dyskinesia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Dyskinesia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
  • Dyskinesia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Dyskinesia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Dyskinesia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
  • GlobalData Methodology 211
Back to Top